abiraterone,pembrolizumab,enzalutamide,olaparib,prednisone
astrazeneca,merck,astellas,pfizer,janssen
['keylynk,010', 'olaparib', 'crpc', 'pembro']
p3 keylynk-010 study did not show a statistically significant improvement in rpfs or os with pembrolizumab plus olaparib vs the active comparator nha for participants with molecularly unselected, previously treated mcrpc #esmo22 
Pursuing to improve cancer prevention and care. Medical Oncologist @AnkaraUni